Greece vs Norway: Life science patents granted, by technology
Greece
16 patents
in 2023
Norway
16 patents
in 2023
Greece rank
32nd
Norway rank
32nd
Life science patents granted, by technology over time
- Greece
- Norway
How they compare
Greece currently reports 16 patents against 16 patents in Norway, a difference of 0 patents.
The two have swapped places 3 times across 43 shared years of data; in 1980 it was Greece ahead.
Greece ranks 32nd and Norway ranks 32nd of 65 countries.
Across the 5 decades both report, Greece averaged higher in 1 and Norway in 4.
Head to head by decade
| Decade | Greece | Norway | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 253.22 patents | 87.56 patents | 165.67 patents | Greece |
| 1990s | 27 patents | 203.9 patents | 176.9 patents | Norway |
| 2000s | 14.4 patents | 238.5 patents | 224.1 patents | Norway |
| 2010s | 21.2 patents | 170.1 patents | 148.9 patents | Norway |
| 2020s | 19 patents | 26.75 patents | 7.75 patents | Norway |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher life science patents granted, by technology, Greece or Norway?
- Greece, at 16 patents against 16 patents in Norway as of 2023.
- What is the difference in life science patents granted, by technology between Greece and Norway?
- 0 patents, with Greece ahead.
- How many years of comparable data are there for Greece and Norway?
- 43 years are reported by both, from 1980 to 2023.
- How do Greece and Norway rank globally for life science patents granted, by technology?
- Greece ranks 32nd and Norway ranks 32nd of 65 countries.
- Where does this data come from?
- World Intellectual Property Organization (WIPO) (2025) β processed by Our World in Data, published as Life science patents granted, by technology. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of pharmaceutical patents granted by the filing office in a given year. Pharmaceutical patents typically cover new drugs, biological treatments or vaccines.